Abstract:Recent availability of immune checkpoint inhibitors has facilitated research involving programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1). However, the incidence and clinical implication of PD-1 and PD-L1 expression in prostate cancer remain poorly understood. The current study aimed to determine the status of PD-1/PD-L1 expression in prostate cancer specimens and its prognostic significance.We immunohistochemically stained for PD-1 and PD-L1 in our tissue microarray (TMA) consisting of radical prostatectomy specimens. The expression of PD-1/PD-L1 was designated as positive when moderate to strong staining or weak staining was seen in at least 1% or 10%, respectively, of tumor cells and/or associated immune cells. We then evaluated the relationship between the expression of each protein and clinicopathological features available for our patient cohort.PD-1 and PD-L1 were positive in 3 (1.5%) and 1 (0.5%) of 201 non-neoplastic prostate tissues, and also in 17 (7.7%) and 29 (13.2%) of 220 prostate cancers, respectively. PD-1 and PD-L1 were also expressed in tumor-infiltrating lymphocytes/macrophages in 172 (78.2%) and 33 (15.0%) cases, respectively. PD-L1 expression in tumor cells was more often seen in high pT stage (pT2: 10.8% vs pT3/4: 20.4%; P = .072; pT2/3a: 11.4% vs pT3b/4: 31.6%; P = .013) or lymph node-positive (pN0: 10.1% vs pN1: 27.3%; P = .086) cases, whereas PD-1 expression in tumor cells was not significantly associated with pT/pN stage. In addition, there were no statistically significant associations between PD-1/PD-L1 expression in tumor cells or tumor-infiltrating lymphocytes/macrophages versus patient age, preoperative prostate-specific antigen level, or Gleason score. Kaplan-Meier analysis coupled with log-rank test further revealed no significant associations between PD-1/PD-L1 expression in tumor cells (P = .619/P = .315), tumor-infiltrating lymphocytes/macrophages (P = .954/P = .155), or either or both of them (P = .964/P = .767) versus disease recurrence after radical prostatectomy.PD-1/PD-L1 expression was detected in a subset of prostate cancers. In particular, PD-L1 expression was considerably up-regulated in nonorgan-confined tumors. However, PD-1/PD-L1 expression in our TMA was found to be not very helpful in predicting tumor recurrence in prostate cancer patients who underwent radical prostatectomy.

Expression And Clinical Significance Of The Nin One Binding Protein And P38 Mapk In Prostate Carcinoma

Positive Nin One Binding Protein Expression Predicts Poor Outcome in Prostate Cancer.

Nin one binding protein expression as a prognostic marker in prostate carcinoma

Clinical Significance of Nob1 Expression in Breast Infiltrating Ductal Carcinoma

Expression of Nucleosomal Binding Protein 1 in Normal Prostate Benign Prostate Hyperplasia, and Prostate Cancer and Significance Thereof

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Inhibitor of DNA Binding-1 Overexpression in Prostate Cancer: Relevance to Tumor Differentiation

Pan-cancer exploration of PNO1: A prospective prognostic biomarker with ties to immune infiltration

Prognostic Value of NOB1 Expression Levels in Various Cancers: a Systematic Review and Meta-Analysis.

Classical and Alternative Nuclear Factor-κB Pathways: A Comparison among Normal Prostate, Benign Prostate Hyperplasia and Prostate Cancer

Analysis of clinical significance of p27 and OPN in Prostate cancer tissues

EXPRESSION MECHANISM AND CLINICAL SIGNIFICANCE OF NOB1 IN GASTRIC CANCER TISSUE AND ADJACENT NORMAL TISSUE.

Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer

Relationship between loss of 53BP1 expression and clinical pathology in prostate adenocarcinoma

NOB1 Gene As a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer.

Upregulation of COPB2 Promotes Prostate Cancer Proliferation and Invasion Through the MAPK/TGF-β Signaling Pathway

PCAT-1 Expression is Associated with the Prognosis in Prostate Cancer.

Potential Role of the OPG/RANK/RANKL Axis in Prostate Cancer Invasion and Bone Metastasis

Overexpression of BUB1B Contributes to Progression of Prostate Cancer and Predicts Poor Outcome in Patients with Prostate Cancer

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer

Ppp5c Promotes Cell Proliferation And Survival In Human Prostate Cancer By Regulating Of The Jnk And Erk 1/2 Phosphorylation